The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.

Szczegóły

Tytuł:: The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Autorzy:: McMillan A; University College London Hospitals NHS Foundation Trust, London, UK.
O'Neill AT; University College London Hospitals NHS Foundation Trust, London, UK.
Townsend W; University College London Hospitals NHS Foundation Trust, London, UK.
Lambert J; University College London Hospitals NHS Foundation Trust, London, UK.
Virchis A; University College London Hospitals NHS Foundation Trust, London, UK.
Shah R; University College London Hospitals NHS Foundation Trust, London, UK.
Menezes L; University College London Hospitals NHS Foundation Trust, London, UK.
Humphries P; University College London Hospitals NHS Foundation Trust, London, UK.
Von Both K; University College London Hospitals NHS Foundation Trust, London, UK.
Grandage V; University College London Hospitals NHS Foundation Trust, London, UK.
Carpenter B; University College London Hospitals NHS Foundation Trust, London, UK.
Hough R; University College London Hospitals NHS Foundation Trust, London, UK.
Ardeshna KM; University College London Hospitals NHS Foundation Trust, London, UK.
Daw S; University College London Hospitals NHS Foundation Trust, London, UK.
Źródło:: British journal of haematology [Br J Haematol] 2021 Feb; Vol. 192 (3), pp. e84-e87. Date of Electronic Publication: 2021 Jan 10.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adolescent ; Adult ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Child ; Female ; Humans ; Male ; Treatment Outcome ; Young Adult
References:: Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152:249-60.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40-8.
Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665-70.
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-e461.
Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456-60.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020;189(3):e86-e90.
Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019;9(12):100.
Kalac M, Lue JK, Lichtenstein E, Turenne I, Rojas C, Amengual JE, et al. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Br J Haematol. 2018;180(5):757-60.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257-66.
Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, et al. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. Eur J Haematol. 2020;104(3):251-8.
Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019;3:1546-52.
Luciana Vinti FL, Merli P, Parasole R, Buffardi S, Pillon M, Strocchio L, et al. Brentuximab vedotin in combination with bendamustine in relapsed or refractory Hodgkin Lymphoma: a retrospective analysis on 23 paediatric patients or young adults. Blood. 2017;130:4090-90.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
Institute NIoHaNC. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 27/11/2017 [cited 2020 04/08/2020]; Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Grant Information:: MR/S000135/1 United Kingdom MRC_ Medical Research Council; MR/S000135/2 United Kingdom MRC_ Medical Research Council
Contributed Indexing:: Keywords: Bendamustine; Brentuximab; Hodgkin lymphoma; Refractory; Relapse; Salvage
Substance Nomenclature:: 0 (Antineoplastic Agents, Alkylating)
0 (Antineoplastic Agents, Immunological)
7XL5ISS668 (Brentuximab Vedotin)
981Y8SX18M (Bendamustine Hydrochloride)
Entry Date(s):: Date Created: 20210111 Date Completed: 20210622 Latest Revision: 20240313
Update Code:: 20240313
DOI:: 10.1111/bjh.17274
PMID:: 33426648
: Opinia redakcyjna

Full Text Finder

Informacja